DHL Global Forwarding enhances logistics for specialty pharmaceuticals, ensuring fast delivery and strict compliance for sensitive therapies.
DHL Global Forwarding is reshaping its logistics operations to meet the demands of specialty pharmaceuticals such as cell and gene therapies, reported DHL.
Unlike traditional bulk shipments, these therapies require faster delivery, ultra-low temperature control, and full visibility. DHL stated that the margin for error is shrinking as treatments often have short shelf lives, narrow temperature ranges, and strict regulatory oversight.
Some therapies involve radioactive materials or must be delivered to remote markets with limited infrastructure. DHL noted that delays or temperature deviations could jeopardize entire shipments, making precise planning and risk management essential.
The company highlighted its capabilities, including end-to-end temperature-controlled transport, validated packaging, real-time monitoring, and GxP-compliant processes. DHL also cited proactive risk management measures such as lane validation and contingency planning.
Infrastructure tailored to pharmaceutical needs, including specialized hubs and cold storage, supports these operations. DHL emphasized that collaboration across its divisions ensures handling, warehousing, and distribution under the DHL Health Logistics brand.
With decades of experience in health logistics, DHL Global Forwarding stated it is positioned to deliver reliable solutions for both high-volume and specialty shipments, maintaining product integrity and compliance at every stage.
